Key result
CVMI enables early detection of cancer therapy-related cardiac dysfunction to facilitate prompt cardioprotective therapy.
Why the study?
Cancer therapies frequently cause cardiovascular adverse events, making cardiovascular multimodality imaging essential for baseline evaluation, early detection, and surveillance of cardiotoxicity.
This narrative review highlights the essential role of multimodality imaging, particularly echocardiography and CMR, in the early detection and management of cardiovascular toxicities in cancer patients.
May inform cardio-oncology surveillance; leaves open prospective trials to confirm outcome benefits.
Recent advances in oncology have contributed to a steady rise in cancer survivorship. However, many cancer therapies are associated with cardiovascular adverse events, leading to increased rates of cardiovascular morbidity and mortality. As a result, cardio-oncology has emerged as a rapidly advancing discipline that relies on multidisciplinary collaboration. Cardiovascular multimodality imaging (CVMI) is an essential diagnostic and surveillance tool for cardiovascular toxicity, along with clinical evaluation and biomarkers. CVMI plays a central role in diagnosing cancer therapy-related cardiac dysfunction (CTRCD) and myocarditis, while also supporting the assessment of vascular toxicity and arrhythmias. It is essential for baseline cardiac evaluation and continuous monitoring throughout and following cancer therapy. CVMI enables early detection of cardiovascular toxicity, facilitating prompt initiation of cardioprotective therapy and allowing cancer therapy to proceed without compromising safety. Echocardiography is the primary imaging modality for screening, diagnosing, and monitoring CTRCD. Moreover, it is the first-line imaging test for cardiac structural and functional assessment in patients who develop immune checkpoint inhibitor (ICI)-related myocarditis. Advanced imaging techniques, such as cardiac magnetic resonance (CMR), nuclear imaging, and cardiac computed tomography, may help determine the cause and severity of left ventricular dysfunction, as well as assess cardiac masses and vascular toxicity. Not least, CMR is the gold standard imaging modality to diagnose myocarditis. This article is a narrative review that focuses on the various modalities of CVMI and their applications in cardio-oncology. Since the issue addressed is very extensive, this review was designed to be concise.
No takes yet. Share an insight, caveat, or question.
Mateescu et al. (2026) studied this question. Cardiovascular multimodality imaging (CVMI) enables early detection of cancer therapy-related cardiac dysfunction, facilitating prompt cardioprotective therapy initiation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: